​

Aerovate Therapeutics (AVTE) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

AVTE Stock Forecast

Aerovate Therapeutics (AVTE) stock forecast, based on 6 Wall Street analysts, predicts a 12-month average price target of $13.00, with a high of $35.00 and a low of $2.00. This represents a 383.27% increase from the last price of $2.69.

- $7 $14 $21 $28 $35 High: $35 Avg: $13 Low: $2 Last Closed Price: $2.69

AVTE Stock Rating

Aerovate Therapeutics stock's rating consensus is Hold, based on 6 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 2 Buy (33.33%), 4 Hold (66.67%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Hold
Total 6 0 4 2 Strong Sell Sell Hold Buy Strong Buy

AVTE Price Target Upside V Benchmarks

TypeNameUpside
StockAerovate Therapeutics383.27%
SectorHealthcare Stocks 33.91%
IndustryBiotech Stocks 83.49%

Price Target Trends

1M3M12M
# Anlaysts--2
Avg Price Target--$2.00
Last Closing Price$2.69$2.69$2.69
Upside/Downside---25.65%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 25--4--4
Mar, 25--4--4
Feb, 25--4--4
Jan, 25--4--4
Dec, 24--4--4
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jun 17, 2024Liisa BaykoEvercore ISI$2.00$1.6521.21%-25.65%
Jun 17, 2024Eun YangJefferies$2.00$1.6521.21%-25.65%
Apr 01, 2024Tiago FauthWells Fargo$35.00$29.5718.36%1201.12%
Mar 25, 2024Eun YangJefferies$65.00$26.95141.19%2316.36%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jun 18, 2024Wells FargoOverweightEqual-Weightdowngrade
Jun 17, 2024Cowen & Co.Holddowngrade
Jun 17, 2024GuggenheimNeutraldowngrade
Jun 17, 2024JefferiesHolddowngrade
Jun 17, 2024BTIGBuyNeutraldowngrade
Apr 01, 2024Wells FargoOverweightOverweighthold
Dec 06, 2022BTIGBuyupgrade

Financial Forecast

EPS Forecast

Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.87$-2.44----
Avg Forecast$-2.79$-2.63$-0.69$-2.01$-0.70$-0.72
High Forecast$-2.77$-2.42$-0.44$-1.11$-0.70$-0.72
Low Forecast$-2.81$-2.84$-0.94$-2.91$-0.70$-0.72
Surprise %2.87%-7.22%----

Revenue Forecast

$20M $21M $21M $22M $22M $23M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast---$20.37M$21.99M$22.97M
High Forecast---$20.37M$21.99M$22.97M
Low Forecast---$20.37M$21.99M$22.97M
Surprise %------

Net Income Forecast

$-80M $-66M $-52M $-38M $-24M $-10M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-75.52M$-69.63M----
Avg Forecast$-73.40M$-69.25M$-24.45M$-52.93M$-18.43M$-18.96M
High Forecast$-72.88M$-63.74M$-11.68M$-29.28M$-18.43M$-18.96M
Low Forecast$-73.92M$-74.76M$-24.66M$-76.57M$-18.43M$-18.96M
Surprise %2.89%0.54%----

AVTE Forecast FAQ

Is Aerovate Therapeutics stock a buy?

Aerovate Therapeutics stock has a consensus rating of Hold, based on 6 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 2 Buy, 4 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Aerovate Therapeutics is a neutral investment for most analysts.

What is Aerovate Therapeutics's price target?

Aerovate Therapeutics's price target, set by 6 Wall Street analysts, averages $13 over the next 12 months. The price target range spans from $2 at the low end to $35 at the high end, suggesting a potential 383.27% change from the previous closing price of $2.69.

How does Aerovate Therapeutics stock forecast compare to its benchmarks?

Aerovate Therapeutics's stock forecast shows a 383.27% upside, outperforming the average forecast for the healthcare stocks sector (33.91%) and outperforming the biotech stocks industry (83.49%).

What is the breakdown of analyst ratings for Aerovate Therapeutics over the past three months?

  • April 2025: 0% Strong Buy, 0% Buy, 100.00% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 0% Strong Buy, 0% Buy, 100.00% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 0% Strong Buy, 0% Buy, 100.00% Hold, 0% Sell, 0% Strong Sell.

What is Aerovate Therapeutics’s EPS forecast?

Aerovate Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-0.69, marking a -71.72% decrease from the reported $-2.44 in 2024. Estimates for the following years are $-2.01 in 2026, $-0.7 in 2027, and $-0.72 in 2028.

What is Aerovate Therapeutics’s revenue forecast?

Aerovate Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $0, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $20.37M, followed by $21.99M for 2027, and $22.97M for 2028.

What is Aerovate Therapeutics’s net income forecast?

Aerovate Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-24.45M, representing a -64.88% decrease from the reported $-69.628M in 2024. Projections indicate $-52.927M in 2026, $-18.432M in 2027, and $-18.959M in 2028.